Related Experiment Video
Updated: Feb 16, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
Jonas Graf1, Verena I Leussink1, Thomas Dehmel2
1Department of Neurology University Hospital Medical Faculty Heinrich-Heine-University Düsseldorf Germany.
Abstract:
The increasing number of potent treatments for multiple sclerosis warrants screening for infections. To investigate the prevalence of infections in two independent German patient cohorts with multiple sclerosis/neuromyelitis optica spectrum disorders (NMOSD), we performed a retrospective chart review study of multiple sclerosis/NMOSD patients who underwent testing for infections between 2014 and 2016. We show that 6 out of 80 tested patients (Düsseldorf cohort) and 2 out of 97 tested patients (Münster cohort) had a latent tuberculosis infection; total 3.95%, 95% CI: 2-8%. Our findings suggest that latent tuberculosis infection is frequent (>1%). Screening should be performed before embarking on immunomodulatory therapies to allow treatment and mitigation of the risk of a reactivation.
Insights
Latent tuberculosis infection is common in German multiple sclerosis patients. Screening before immunotherapy is crucial to prevent tuberculosis reactivation during treatment for multiple sclerosis or NMOSD.
Area of Science:
- Neurology
- Infectious Diseases
- Immunology
Background:
- Potent treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) necessitate infection screening.
- Latent infections pose a risk of reactivation during immunosuppressive therapy.
Purpose of the Study:
- To determine the prevalence of infections, specifically latent tuberculosis infection (LTBI), in German patients with MS/NMOSD.
- To assess the need for pre-treatment screening for LTBI in this patient population.
Main Methods:
- Retrospective chart review of MS/NMOSD patients who underwent infection testing between 2014 and 2016.
- Analysis of two independent German patient cohorts (Düsseldorf and Münster).
Main Results:
- Latent tuberculosis infection was identified in 3.95% of tested patients (95% CI: 2-8%).
- Specifically, 6 out of 80 patients in the Düsseldorf cohort and 2 out of 97 in the Münster cohort had LTBI.
- The prevalence of LTBI exceeded 1% in both cohorts.
Conclusions:
- Latent tuberculosis infection is a frequent comorbidity in German patients with MS/NMOSD.
- Routine screening for LTBI is recommended before initiating immunomodulatory therapies.
- Early detection and treatment of LTBI can mitigate the risk of reactivation during MS/NMOSD treatment.
Related Concept Videos
Tumor Immunotherapy
Receiver Operating Characteristic Plot
Relative Risk
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Multiple Allele Traits
Drug Toxicity: Risk factors

